MCMukesh Chourasia

Mukesh Chourasia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mukesh Chourasia has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Levonorgestrel-induced modulation of triple negative breast cancer proliferation via glucocorticoid receptor

    by Banashree Bondhopadhyay, Navya Aggarwal, Mukesh Chourasia, Sandeep Sisodiya, Showket Hussain

    Indiscriminate use of levonorgestrel, a progestin-only contraceptive, can affect breast cancer subtypes, as it can plausibly bind to steroid receptors other than Estrogen Receptor (ER) and Progesterone Receptor (PR). The ER, PR negative status of TNBC makes it important to explore other receptors of levonorgestrel. In this study glucocorticoid receptor (GR) was observed to show − 83.519 kcal/mol free energy of binding with levonorgestrel. To understand the effect of levonorgestrel on breast cancer cells, cellular assays were performed. In the cell proliferation assays, it was found that ER + PR + Her2- cell line, MCF-7, showed reduced proliferation upon treatment with levonorgestrel for 24 h. Whereas TNBC cell lines (MDA-MB-231 and MDA-MB-468) showed statistically significantly higher proliferation rate. Cellular adhesion assays displayed more adhesion in levonorgestrel-treated MCF-7 cells than in levonorgestrel-treated MDA-MB-231 and MDA-MB-468, as compared to the control. Ki67 (proliferation marker) showed upregulation in MCF-7 control. Levonorgestrel-treated MCF-7 cells demonstrated Ki67 downregulation. In contrast, the treatment triggered upregulation of Ki67 in TNBC cell lines on levonorgestrel treatment. Therefore, the study suggests that in the absence of ER and PR in TNBC, levonorgestrel may potentially show its effect through GR. The study emphasizes the need for further research, as there exist several factors, such as the consumption of oral contraceptive pills like levonorgestrel, which might worsen the status of breast cancer in women.


  • Open Access

    Fenchone Derivatives as a Novel Class of CB2 Selective Ligands: Design, Synthesis, X-ray Structure and Therapeutic Potential

    by Reem Smoum, Christeene Haj, Shira Hirsch, Alina Nemirovski, Zhannah Yekhtin, Benny Bogoslavsky, Gaganjyot Kaur Bakshi, Mukesh Chourasia, Ruth Gallily, Joseph Tam, et al.

    A series of novel cannabinoid-type derivatives were synthesized by the coupling of (1S,4R)-(+) and (1R,4S)-(−)-fenchones with various resorcinols/phenols. The fenchone-resorcinol derivatives were fluorinated using Selectfluor and demethylated using sodium ethanethiolate in dimethylformamide (DMF). The absolute configurations of four compounds were determined by X-ray single crystal diffraction. The fenchone-resorcinol analogs possessed high affinity and selectivity for the CB2 cannabinoid receptor. One of the analogues synthesized, 2-(2′,6′-dimethoxy-4′-(2″-methyloctan-2″-yl)phenyl)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-ol (1d), had a high affinity (Ki = 3.51 nM) and selectivity for the human CB2 receptor (hCB2). In the [35S]GTPγS binding assay, our lead compound was found to be a highly potent and efficacious hCB2 receptor agonist (EC50 = 2.59 nM, E(max) = 89.6%). Two of the fenchone derivatives were found to possess anti-inflammatory and analgesic properties. Molecular-modeling studies elucidated the binding interactions of 1d within the CB2 binding site.


  • Open Access

    Takinib Inhibits Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts by Targeting the Janus Kinase-Signal Transducer and Activator of Transcription 3 (JAK/STAT3) Pathway

    by Paul M. Panipinto, Anil K. Singh, Farheen S. Shaikh, Ruby J. Siegel, Mukesh Chourasia, Salahuddin Ahmed

    TGF β-activated kinase 1 (TAK1) is an important participant in inflammatory pathogenesis for diseases such as rheumatoid arthritis (RA) and gouty arthritis. The central position it occupies between the mitogen activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) pathways makes it an attractive therapeutic target. As this field has developed in recent years, several novel inhibitors have been presented as having specific activity that reduces the TAK1 function either covalently as in the case of 5Z-7-oxozeanol (5Z7O) or reversibly (NG-25). However, the mechanism through which takinib elicits its anti-inflammatory activity remains elusive. While this inhibitor shows great promise, a thorough analysis of its inhibitor function and its potential off-target effects is necessary before addressing its clinical potential or its use in inflammatory conditions. An analysis through Western blot showed an unexpected increase in IL-1β-induced TAK1 phosphorylation—a prerequisite for and indicator of its functional potential—by takinib while simultaneously demonstrating the inhibition of the JAK/STAT pathway in human rheumatoid arthritis synovial fibroblasts (RASFs) in vitro. In THP-1 monocyte-derived macrophages, takinib again led to the lipopolysaccharide-induced phosphorylation of TAK1 without a marked inhibition of the TAK1 downstream effectors, namely, of c-Jun N-terminal kinase (JNK), phospho-c-Jun, NF-κB phospho-p65 or phospho-IκBα. Taken together, these findings indicate that takinib inhibits inflammation in these cells by targeting multiple signaling pathways, most notably the JAK/STAT pathway in human RASFs.


  • Open Access

    Lead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approaches

    by Akbar Ali Khan Pathan, Bhavana Panthi, Zahid Khan, Purushotham Reddy Koppula, Mohammad Alanazi, Narasimha Reddy Parine, Mukesh Chourasia, S Sachchidanand

    Objective: Kirsten rat sarcoma (K-Ras) protein is a member of Ras family belonging to the small guanosine triphosphatases superfamily. The members of this family share a conserved structure and biochemical properties, acting as binary molecular switches. The guanosine triphosphate-bound active K-Ras interacts with a range of effectors, resulting in the stimulation of downstream signaling pathways regulating cell proliferation, differentiation, and apoptosis. Efforts to target K-Ras have been unsuccessful until now, placing it among high-value molecules against which developing a therapy would have an enormous impact. K-Ras transduces signals when it binds to guanosine triphosphate by directly binding to downstream effector proteins, but in case of guanosine diphosphate-bound conformation, these interactions get disrupted. Methods: In the present study, we targeted the nucleotide-binding site in the “on” and “off” state conformations of the K-Ras protein to find out suitable lead compounds. A structure-based virtual screening approach has been used to screen compounds from different databases, followed by a combinatorial fragment-based approach to design the apposite lead for the K-Ras protein. Results: Interestingly, the designed compounds exhibit a binding preference for the “off” state over “on” state conformation of K-Ras protein. Moreover, the designed compounds’ interactions are similar to guanosine diphosphate and, thus, could presumably act as a potential lead for K-Ras. The predicted drug-likeness properties of these compounds suggest that these compounds follow the Lipinski’s rule of five and have tolerable absorption, distribution, metabolism, excretion and toxicity values. Conclusion: Thus, through the current study, we propose targeting only “off” state conformations as a promising strategy for the design of reversible inhibitors to pharmacologically inhibit distinct conformations of K-Ras protein.